A year after a long-running clinical hold was lifted on MaaT Pharma’s pooled fecal therapy, the microbiome biotech has touted 18-month data as proof it’s on track to launch the drug in acute ...
MaaT Pharma’s 18-month struggle to get out from under an FDA clinical hold may be entering its endgame. In its latest feedback, the agency reportedly agreed to a list of conditions that could enable ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
In June 2025, the European Medicines Agency accepted for review the marketing authorization submission for this medicine MaaT Pharma will receive a €10.5 million upfront payment, further potential ...
Tranche-based financing to support clinical development for the Company’s late-stage assets in hemato-oncology including Xervyteg ® currently under review for potential approval by the EMA and MaaT033 ...
LYON, France--(BUSINESS WIRE)--Regulatory News: These encouraging findings from the IASO Phase 1b trial confirm the favorable safety and tolerability profile of MaaT033 in ALS patients. They also ...
MaaT Pharma secures important funding in line with one of the goals under the Health Innovation 2030 Plan, the health component of 'France 2030', led by the Health Innovation Agency dedicated to ...
MaaT033, currently in Phase 2b potentially pivotal trial (PHOEBUS), is ongoing and continued to demonstrate a favorable safety profile, with six DSMB reviews completed in 2025. Topline results for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results